Profound Medical Corp. Transforms BPH Treatment with TULSA-PRO and TULSA-AI Integration
- Profound Medical successfully performed its first commercial BPH treatment using TULSA-PRO and TULSA-AI integration on June 10, 2025.
- The TULSA-PRO system uses ultrasound technology for precise prostate tissue ablation, enhancing patient comfort and outcomes.
- Profound Medical aims to innovate in medical technology, focusing on minimally invasive treatments for various conditions.
Profound Medical Revolutionizes BPH Treatment with TULSA-PRO and TULSA-AI Integration
On June 10, 2025, Profound Medical Corp. achieves a significant milestone in urological care by successfully performing its first commercial treatment for benign prostatic hyperplasia (BPH) using the TULSA-PRO® system in conjunction with the newly launched TULSA-AI® Volume Reduction Module. This innovative procedure, executed by Dr. Naveen Kella, represents a notable advancement in the management of BPH, a condition that affects a substantial number of aging men and often leads to lower urinary tract symptoms (LUTS). Traditional interventions such as transurethral resection of the prostate (TURP) have been largely ineffective, with a staggering 96% of patients discontinuing treatment due to complications or dissatisfaction.
The TULSA-PRO system distinguishes itself with its unique approach that utilizes ultrasound technology to precisely target and ablate prostate tissue. This minimizes discomfort and optimizes treatment outcomes. The integration of TULSA-AI significantly enhances procedural efficiency by offering personalized treatment plans tailored to individual patient needs. With the procedure duration reduced to approximately 60-90 minutes, the TULSA-PRO system not only promotes a non-invasive, incision-free experience but also eliminates the need for hospitalization, allowing for quicker recovery times. This innovative framework positions Profound Medical as a leader in minimally invasive therapies for prostate conditions.
Furthermore, the real-time MRI data utilized in the TULSA procedure ensures that essential areas of the prostate are preserved during treatment, enhancing patient safety and comfort. This advanced imaging capability reflects a broader trend in urology towards personalized treatment options that prioritize patient outcomes. Profound Medical's commitment to leveraging cutting-edge technology in its TULSA-PRO system, which is CE marked, Health Canada approved, and has received FDA 510(k) clearance, underscores its role in addressing the longstanding challenges associated with BPH treatment.
In addition to its groundbreaking work with BPH, Profound Medical continues to advance its Sonalleve® platform, targeting non-invasive treatments for uterine fibroids. This reflects the company's broader mission to innovate within the medical technology landscape, focusing on solutions that improve patient experiences and outcomes across various conditions. As Profound Medical expands its market presence, the integration of TULSA-AI with TULSA-PRO emphasizes its dedication to pioneering effective, minimally invasive treatment options in urology.